title: Glycemic and serum lipid control in patients with painful diabetic peripheral neuropathy treated with pregabalin.
abstract: OBJECTIVE
  To evaluate pregabalin effects on glycemic (hemoglobin A1c [HbA1c] and glucose) and lipid (low- and high-density lipoprotein [LDL and HDL, respectively], and total cholesterol, and triglycerides) control in patients with painful diabetic peripheral neuropathy (pDPN).
  
  
  METHODS
  Data from 11 randomized, double-blind trials were pooled to assess change-from-baseline treatment differences (pregabalin or placebo) in glycemic and lipid parameters using analysis of covariance.
  
  
  RESULTS
  Patients received pregabalin doses (mg/d) of 150 (n=176), 300 (n=559), 600 (n=705), 150-600 (flexible dose, n=521), or placebo (n=1050). Statistically significant mean [95% confidence interval] within-treatment (pregabalin) changes occurred in HDL (600mg/d: -1.61mg/dl [-3.17, -0.05]), total cholesterol (flexible dose: -6.03mg/dl [-11.68, -0.39]), and triglycerides (flexible dose: +15.39mg/dl [1.56, 29.23]). Statistically significant differences from placebo were found in HbA1c (300mg/d: +0.11% [0.01, 0.21]) and HDL cholesterol (300mg/d: -1.78mg/dl [-3.36, -0.19], 600mg/d: -2.53mg/dl [-4.49, -0.57]). No within- or between-treatment changes were large enough to be clinically meaningful.
  
  
  CONCLUSIONS
  No apparent clinically meaningful effects of pregabalin on glycemic/lipid control were found in patients with pDPN.
authors.affiliation: Pfizer, New York, NY, USA. Electronic address: Bruce.Parsons@pfizer.com.
authors.forename: Bruce
authors.initials: B
authors.lastname: Parsons
authors.affiliation: Pfizer, New York, NY, USA.
authors.forename: Birol
authors.initials: B
authors.lastname: Emir
mesh_terms: D000328:Adult; D000700:Analgesics / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D001786:Blood Glucose / Q000032:analysis; D002784:Cholesterol / Q000097:blood; D003928:Diabetic Nephropathies / Q000097:blood / Q000188:drug therapy*; D004305:Dose-Response Relationship, Drug; D004311:Double-Blind Method; D006442:Glycated Hemoglobin / Q000032:analysis; D006801:Humans; D008075:Lipoproteins, HDL / Q000097:blood; D008077:Lipoproteins, LDL / Q000097:blood; D010146:Pain / Q000097:blood / Q000150:complications / Q000188:drug therapy*; D010523:Peripheral Nervous System Diseases / Q000097:blood / Q000150:complications / Q000188:drug therapy*; D000069583:Pregabalin / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D016032:Randomized Controlled Trials as Topic; D015203:Reproducibility of Results; D014280:Triglycerides / Q000097:blood
chemical_list: D000700:Analgesics; D001786:Blood Glucose; D002784:Cholesterol; D006442:Glycated Hemoglobin; D008075:Lipoproteins, HDL; D008077:Lipoproteins, LDL; D000069583:Pregabalin; D014280:Triglycerides; C517652:hemoglobin A1c protein, human
keywords: Blood glucose; Diabetic peripheral neuropathy; Hemoglobin A1c; Lipids; Pregabalin